Harbour BioMed Announced NMPA Approval For LET003 For The Treatment of Obesity
Harbour BioMed announced that China’s National Medical Products Administration (NMPA) accepted the Investigational New Drug (IND) application for its LET003, its first next-generation ACVR2A/2B-targeting monoclonal antibody developed using the Hu-mAtrix AI platform, for the treatment of overweight or obesity.

About LET003
LET003 is a next-generation monoclonal antibody targeting dual activin receptors ACVR2A and ACVR2B. The drug demonstrated a promising approach in preclinical and clinical studies with superior pharmacokinetic characteristics. LET003 achieved enhanced fat reduction compared to semaglutide, while preserving lean mass. LET003 also showed lean mass-promoting effects at a lower dose level compared to bimagrumab at a higher dose level.
Extensive preclinical and clinical studies have shown that combining a dual ACVR2A/2B inhibitor with GLP-1 weight-loss drugs can further reduce body fat while effectively mitigating lean mass loss. Activin receptors ACVR2A and ACVR2B play vital roles in regulating muscle and fat homeostasis. LET003 is the first dual ACVR2A/2B inhibitor that is developed using the Hu-mAtrix AI platform.
Expert Opinion
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented that the NMPA’s acceptance of the IND application of LET003 marks a significant milestone for the company. The company focuses on advancing LET003 through clinical development and further realizing the potential of its AI-enabled drug discovery capabilities to address significant unmet medical needs.
Dr. Bob Zhang, President of the Metabolic Disease Franchise at Harbour BioMed, stated that obesity treatment is evolving beyond weight reduction alone toward improving body composition and achieving more sustainable health outcomes. The company believes that LET003 has the potential to offer a differentiated therapeutic approach and look forward to evaluating its potential in clinical development.
About Harbour BioMed
Harbour BioMed is a China-based global biopharmaceutical company that focuses on the discovery and development of novel antibody therapeutics in immunology, oncology, and other areas. It is building a robust portfolio and a differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
The company’s proprietary technology platform includes Harbour Mice, HCAb-based immune cell engagers (HBICE) bispecific antibody technology, and HCAb-based Antibody Plus technology (HCAb PLUS). By integrating these platforms, Harbour BioMed has built an efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies.